相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The role of cladribine in acute myeloid leukemia: an old drug up to new tricks
Matteo Molica et al.
LEUKEMIA & LYMPHOMA (2020)
Genetic mechanisms of primary chemotherapy resistance in pediatric acute myeloid leukemia
Nicole A. McNeer et al.
LEUKEMIA (2019)
Mechanisms of drug resistance in acute myeloid leukemia
Jing Zhang et al.
ONCOTARGETS AND THERAPY (2019)
Targeting CLL-1 for acute myeloid leukemia therapy
Hongbing Ma et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)
g:Profiler: a web server for functional enrichment analysis and conversions of gene lists (2019 update)
Uku Raudvere et al.
NUCLEIC ACIDS RESEARCH (2019)
Surmounting Cytarabine-resistance in acute myeloblastic leukemia cells and specimens with a synergistic combination of hydroxyurea and azidothymidine
May Levin et al.
CELL DEATH & DISEASE (2019)
Targeting FLT3 mutations in AML: review of current knowledge and evidence
Naval Daver et al.
LEUKEMIA (2019)
Isocitrate dehydrogenase inhibitors in acute myeloid leukemia
Xiaoyan Liu et al.
BIOMARKER RESEARCH (2019)
Successes and challenges in the treatment of pediatric acute myeloid leukemia: a retrospective analysis of the AML-BFM trials from 1987 to 2012
Mareike Rasche et al.
LEUKEMIA (2018)
MEF2C Phosphorylation Is Required for Chemotherapy Resistance in Acute Myeloid Leukemia
Fiona C. Brown et al.
CANCER DISCOVERY (2018)
SAMHD1 is a biomarker for cytarabine response and a therapeutic target in acute myeloid leukemia
Constanze Schneider et al.
NATURE MEDICINE (2017)
Synergistic functions of E2F7 and E2F8 are critical to suppress stress-induced skin cancer
I. Thurlings et al.
ONCOGENE (2017)
TFDP3 confers chemoresistance in minimal residual disease within childhood T-cell acute lymphoblastic leukemia
Ming Chu et al.
ONCOTARGET (2017)
Chemotherapy-Resistant Human Acute Myeloid Leukemia Cells Are Not Enriched for Leukemic Stem Cells but Require Oxidative Metabolism
Thomas Farge et al.
CANCER DISCOVERY (2017)
Resistance of leukemia cells to cytarabine chemotherapy is mediated by bone marrow stroma, involves cell-surface equilibrative nucleoside transporter-1 removal and correlates with patient outcome
Patricia Macanas-Pirard et al.
ONCOTARGET (2017)
Chemogenomic Landscape of RUNX1-mutated AML Reveals Importance of RUNX1 Allele Dosage in Genetics and Glucocorticoid Sensitivity
Laura Simon et al.
CLINICAL CANCER RESEARCH (2017)
Folylpolyglutamate synthetase splicing alterations in acute lymphoblastic leukemia are provoked by methotrexate and other chemotherapeutics and mediate chemoresistance
Anna Wojtuszkiewicz et al.
INTERNATIONAL JOURNAL OF CANCER (2016)
Complex heatmaps reveal patterns and correlations in multidimensional genomic data
Zuguang Gu et al.
BIOINFORMATICS (2016)
E2f8 mediates tumor suppression in postnatal liver development
Lindsey N. Kent et al.
JOURNAL OF CLINICAL INVESTIGATION (2016)
Upregulation of E2F8 promotes cell proliferation and tumorigenicity in breast cancer by modulating G1/S phase transition
Liping Ye et al.
ONCOTARGET (2016)
Dectin-1 predicts adverse postoperative prognosis of patients with clear cell renal cell carcinoma
Yu Xia et al.
SCIENTIFIC REPORTS (2016)
Geraniol suppresses prostate cancer growth through down-regulation of E2F8
Sanghoon Lee et al.
CANCER MEDICINE (2016)
Hypoxia and Hypoxia-inducible Factors in Leukemias
Margaux Deynoux et al.
FRONTIERS IN ONCOLOGY (2016)
E2F8 as a Novel Therapeutic Target for Lung Cancer
Sin-Aye Park et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2015)
E2F8 as a Novel Therapeutic Target for Lung Cancer
Sin-Aye Park et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2015)
STRING v10: protein-protein interaction networks, integrated over the tree of life
Damian Szklarczyk et al.
NUCLEIC ACIDS RESEARCH (2015)
Gene Expression Profiles Associated with Pediatric Relapsed AML
Costa Bachas et al.
PLOS ONE (2015)
Overexpression of E2F1 in human gastric carcinoma is involved in anti-cancer drug resistance
Lin-Hai Yan et al.
BMC CANCER (2014)
The Role of STAT3 Signaling in Mediating Tumor Resistance to Cancer Therapy
Fiona H. Tan et al.
CURRENT DRUG TARGETS (2014)
E2F1 drives chemotherapeutic drug resistance via ABCG2
M. T. Rosenfeldt et al.
ONCOGENE (2014)
A therapeutically targetable mechanism of BCR-ABL-independent imatinib resistance in chronic myeloid leukemia
Leyuan Ma et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
Antileukemic Activity and Mechanism of Drug Resistance to the Marine Salinispora tropica Proteasome Inhibitor Salinosporamide A (Marizomib)
Denise Niewerth et al.
MOLECULAR PHARMACOLOGY (2014)
Hypoxia-inducing factors as master regulators of stemness properties and altered metabolism of cancer- and metastasis-initiating cells
Murielle Mimeault et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2013)
Improved Outcome in Pediatric Relapsed Acute Myeloid Leukemia: Results of a Randomized Trial on Liposomal Daunorubicin by the International BFM Study Group
Gertjan J. L. Kaspers et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Identification of a 24-Gene Prognostic Signature That Improves the European LeukemiaNet Risk Classification of Acute Myeloid Leukemia: An International Collaborative Study
Zejuan Li et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia
Timothy J. Ley et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Correction: Atypical E2fs Control Lymphangiogenesis through Transcriptional Regulation of Ccbe1 and Flt4
Bart G. M. W. Weijts et al.
PLoS One (2013)
E2F1 apoptosis counterattacked: evil strikes back
Brigitte M. Puetzer et al.
TRENDS IN MOLECULAR MEDICINE (2013)
ABC transporters and their role in nucleoside and nucleotide drug resistance
Yu Fukuda et al.
BIOCHEMICAL PHARMACOLOGY (2012)
Childhood acute myeloid leukaemia
Jeffrey E. Rubnitz et al.
BRITISH JOURNAL OF HAEMATOLOGY (2012)
Pediatric acute myeloid leukemia
Gertjan J. L. Kaspers
EXPERT REVIEW OF ANTICANCER THERAPY (2012)
Cladribine, But Not Fludarabine, Added to Daunorubicin and Cytarabine During Induction Prolongs Survival of Patients With Acute Myeloid Leukemia: A Multicenter, Randomized Phase III Study
Jerzy Holowiecki et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
The role of minor subpopulations within the leukemic blast compartment of AML patients at initial diagnosis in the development of relapse
C. Bachas et al.
LEUKEMIA (2012)
ELF5 Suppresses Estrogen Sensitivity and Underpins the Acquisition of Antiestrogen Resistance in Luminal Breast Cancer
Maria Kalyuga et al.
PLOS BIOLOGY (2012)
High BRE expression predicts favorable outcome in adult acute myeloid leukemia, in particular among MLL-AF9-positive patients
Sylvie M. Noordermeer et al.
BLOOD (2011)
Evaluation of gene expression signatures predictive of cytogenetic and molecular subtypes of pediatric acute myeloid leukemia
Brian V. Balgobind et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2011)
The heterogeneity of pediatric MLL-rearranged acute myeloid leukemia
B. V. Balgobind et al.
LEUKEMIA (2011)
Identification of predictive markers of cytarabine response sin AML by integrative analysis of gene-expression profiles with multiple phenotypes
Jatinder K. Lamba et al.
PHARMACOGENOMICS (2011)
The retinoblastoma tumor suppressor controls androgen signaling and human prostate cancer progression
Ankur Sharma et al.
JOURNAL OF CLINICAL INVESTIGATION (2010)
High BRE expression in pediatric MLL-rearranged AML is associated with favorable outcome
B. V. Balgobind et al.
LEUKEMIA (2010)
E2F1 mediates DNA damage and apoptosis through HCF-1 and the MLL family of histone methyltransferases
Shweta Tyagi et al.
EMBO JOURNAL (2009)
Genetic factors influencing cytarabine therapy
Jatinder K. Lamba
PHARMACOGENOMICS (2009)
Cladribine in the Treatment of Acute Myeloid Leukemia: A Single-Institution Experience
Mike G. Martin et al.
CLINICAL LYMPHOMA & MYELOMA (2009)
Targeting DNA topoisomerase II in cancer chemotherapy
John L. Nitiss
NATURE REVIEWS CANCER (2009)
In vitro cross-resistance to nucleoside analogues and inhibitors of topoisomerase 1 and 2 in acute myeloid leukemia
Michael Fiegl et al.
ANNALS OF HEMATOLOGY (2008)
Molecular mechanisms of drug resistance in acute myeloid leukaemia
Donal P. McLornan et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2007)
CD34-related coexpression of MDR1 and BCRP indicates a clinically resistant phenotype in patients with acute myeloid leukemia (AML) of older age
Marry M. van den Heuvel-Eibrink et al.
ANNALS OF HEMATOLOGY (2007)
Glucose uptake inhibitor sensitizes cancer cells to daunorubicin and overcomes drug resistance in hypoxia
Xianhua Cao et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2007)
Prognostic factors and outcome of recurrence in childhood acute myeloid leukemia
Jeffrey E. Rubnitz et al.
CANCER (2007)
The human equilibrative nucleoside transporter 1 mediates in vitro cytarabine sensitivity in childhood acute myeloid leukaemia
I Hubeek et al.
BRITISH JOURNAL OF CANCER (2005)
Ex vivo drug resistance in childhood acute myeloid leukemia on relapse is not higher than at first diagnosis
J Styczynski et al.
PEDIATRIC BLOOD & CANCER (2004)
Overexpression of E2F1 associated with LOH at RB locus and hyperphosphorylation of RB in non-small cell lung carcinoma
MA Imai et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2004)
Cytoscape: A software environment for integrated models of biomolecular interaction networks
P Shannon et al.
GENOME RESEARCH (2003)
Cellular drug resistance in childhood acute myeloid leukemia is related to chromosomal abnormalities
CM Zwaan et al.
BLOOD (2002)
In vivo mechanisms of resistance to cytarabine in acute myeloid leukaemia
CM Galmarini et al.
BRITISH JOURNAL OF HAEMATOLOGY (2002)
Clinical relevance of in vitro chemoresistance in childhood acute myeloid leukemia
S Yamada et al.
LEUKEMIA (2001)
Nucleoside analogues: mechanisms of drug resistance and reversal strategies
CM Galmarini et al.
LEUKEMIA (2001)
Pretreatment leukaemia cell drug resistance is correlated to clinical outcome in acute myeloid leukaemia
JM Norgaard et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2001)
分享论文
